Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Tulln An Der Donau – page 49

881 clinical trials in Tulln An Der Donau, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Tulln An Der Donau at a glance
881
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

881 trials in Tulln An Der Donau

Open in trial search

Study on Ceralasertib and Trastuzumab Deruxtecan for Patients with Non-Small Cell Lung Cancer After Anti-PD-1/PD-L1 Therapy

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ceralasertib
  • Sponsor:Astrazeneca AB

Study on the Effects and Safety of Efgartigimod PH20 SC for Adults with Active Idiopathic Inflammatory Myopathy

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

K-ras gene mutation+2

Not recruiting

Study Comparing Divarasib, Sotorasib, and Adagrasib for Patients with Advanced or Metastatic KRAS G12C-Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Study on Budesonide Tablets for Treating Eosinophilic Esophagitis in Adults

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:Dr. Falk Pharma GmbH

Uveitis+1

Not recruiting

Study on Izokibep for Patients with Non-infectious Uveitis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Izokibep
  • Sponsor:Acelyrin Inc.

Breast cancer+7

Not recruiting

Study of sacituzumab govitecan compared to standard therapy in HER2-negative breast cancer patients with high risk of relapse after neoadjuvant treatment

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:GBG Forschungs GmbH

Study of emactuzumab compared to placebo in patients with tenosynovial giant cell tumor

Investigational
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Emactuzumab
  • Sponsor:Synox Therapeutics Limited

Multiple sclerosis

Not recruiting

Study on the Effectiveness and Safety of Fenebrutinib and Ocrelizumab for Adults with Primary Progressive Multiple Sclerosis

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Cholangiocarcinoma

Not recruiting

Study Comparing Pemigatinib and Gemcitabine Plus Cisplatin for First-Line Treatment in Patients with Unresectable or Metastatic Cholangiocarcinoma with FGFR2 Rearrangement

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Incyte Corp.

Study on BI 1839100 for Reducing Cough in Patients with Idiopathic or Progressive Pulmonary Fibrosis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:BI 1839100
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study on Anifrolumab for Adults with Chronic or Subacute Cutaneous Lupus Erythematosus Unresponsive to Antimalarial Therapy

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Anifrolumab
  • Sponsor:Astrazeneca AB

Study on BI 1819479 to Improve Lung Function in Patients with Idiopathic Pulmonary Fibrosis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:BI 1819479
  • Sponsor:Boehringer Ingelheim Espana S.A.

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Tulln An Der Donau

What the registry says about research in the country

01 Neurological Disorders

Research focusing on Multiple System Atrophy and its associated conditions, particularly investigating new therapeutic approaches for managing neurogenic orthostatic hypotension. Studies aim to evaluate novel treatments for improving patient symptoms and quality of life.

  • Orthostatic Hypotension Management
  • Autonomic Nervous System Disorders
  • Symptomatic Treatment Evaluation

Current trials are examining long-term effectiveness and durability of new therapeutic interventions.

02 Neuropathic Pain Studies

Comprehensive research into various forms of chronic neuropathic pain, including diabetic polyneuropathy and post-operative peripheral neuropathy. Studies are evaluating new therapeutic options for patients with treatment-resistant conditions.

  • Diabetic Polyneuropathy
  • Traumatic Neuropathy
  • Central Neuropathy

Investigations focus on add-on treatments to enhance current pain management protocols.

03 Chronic Pain Management

Innovative research targeting chronic back pain and various pain conditions, evaluating new therapeutic approaches for improved patient outcomes. Studies are designed to assess both efficacy and tolerability of novel treatment options.

  • Back Pain Treatment
  • Pain Management Protocols
  • Treatment Tolerability Assessment

Current research emphasizes developing comprehensive pain management solutions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.